Osaic Holdings
SPRO icon

Osaic Holdings’s Spero Therapeutics SPRO Stock Holding History

Osaic Holdings’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$678 Hold
290
– – ﹤0.01% 7369
2025
Q4 		$675 Hold
290
– – ﹤0.01% 7384
2025
Q3 		$545 Hold
290
– – ﹤0.01% 7523
2025
Q2 		$841 Buy
+290
New +$417 ﹤0.01% 7214
2025
Q1 		– Sell
-295
Closed -$304 – 7689
2024
Q4 		$304 Hold
295
– – ﹤0.01% 7121
2024
Q3 		$395 Hold
295
– – ﹤0.01% 7049
2024
Q2 		$384 Buy
295
+248
+528% +$374 ﹤0.01% 7048
2024
Q1 		$81 Sell
47
-50
-52% -$78 ﹤0.01% 7053
2023
Q4 		$143 Hold
97
– – ﹤0.01% 7082
2023
Q3 		$117 Sell
97
-2,092
-96% -$2.9K ﹤0.01% 7211
2023
Q2 		$3.26K Sell
2,189
-935
-30% -$1.6K ﹤0.01% 6486
2023
Q1 		$4.86K Buy
3,124
+47
+2% +$79 ﹤0.01% 6329
2022
Q4 		$5K Sell
3,077
-21,740
-88% -$40.6K ﹤0.01% 6309
2022
Q3 		$50K Buy
24,817
+22,022
+788% +$21.9K ﹤0.01% 4902
2022
Q2 		$2K Buy
2,795
+1,700
+155% +$4.94K ﹤0.01% 6936
2022
Q1 		$3.47M Sell
1,095
-30
-3% -$307 0.01% 1473
2021
Q4 		$17K Sell
1,125
-1,423
-56% -$22.6K ﹤0.01% 5911
2021
Q3 		$46K Sell
2,548
-7,515
-75% -$121K ﹤0.01% 5180
2021
Q2 		$143K Sell
10,063
-32,150
-76% -$449K ﹤0.01% 4177
2021
Q1 		$621K Buy
42,213
+29,442
+231% +$518K ﹤0.01% 2652
2020
Q4 		$248K Buy
+12,771
New +$199K ﹤0.01% 3282

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Osaic Holdings's SPRO Position: Q1 2026 in Review

Osaic Holdings held its Spero Therapeutics (SPRO) position steady in Q1 2026 at 290 shares worth $678. The position accounts for ﹤0.01% of the portfolio, ranked #7369.

Osaic Holdings first reported a position in SPRO in Q4 2020 and has held it in 21 quarters since. The position peaked at $3.47M in Q1 2022. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • Osaic Holdings held 290 shares of Spero Therapeutics worth $678 as of Q1 2026.
  • Osaic Holdings left its Spero Therapeutics share count unchanged in Q1 2026.
  • Spero Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q1 2026, its #7369 holding.
  • Osaic Holdings first reported a position in Spero Therapeutics in Q4 2020 and has held it in 21 quarters since.
  • Osaic Holdings's Spero Therapeutics position peaked at $3.47M in Q1 2022.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on Osaic Holdings's 13F filing for Q1 2026, filed 15 May 2026.